STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [Form 4] ELI LILLY & Co Insider Trading Activity

LLY Form 4: Lilly Endowment sells 215,822 shares at $807.85–$833.16

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Lilly Endowment Inc., a reporting person and director for Eli Lilly & Co (LLY), sold a total of 215,822 shares of Eli Lilly common stock on 10/01/2025 across multiple transactions. The sales occurred at weighted‑average prices reported per lot, with transaction price ranges disclosed between $807.85 and $833.155. After these transactions the reported beneficial ownership held indirectly by the reporting person was 95,141,978 shares. The Form 4 covers transactions numbered 31–55 of 55 total for that reporting day and was signed by Diane M. Stenson as Vice President & Treasurer on behalf of Lilly Endowment Inc.

Positive

  • Timely SEC disclosure of multiple insider sales on 10/01/2025
  • Detailed execution ranges provided for each lot, with an offer to supply per‑price quantities on request

Negative

  • Reduction of beneficial holdings by 215,822 shares, lowering reported indirect ownership to 95,141,978
  • Multiple sell transactions across a broad price range which may indicate active disposition on that date

Insights

Large institutional sale disclosed; ownership remains substantial.

The report shows Lilly Endowment Inc. executed 55 total transactions on the reporting date, with 215,822 shares in this Form 4 (transactions #31–55). The filing identifies the reporting person as a director and discloses indirect ownership of 95,141,978 shares following the sales.

This is a routine Section 16 disclosure indicating disposition by a significant holder; it does not state any change in board status or new agreements.

Staggered sales across a wide price band; execution details provided.

The transactions were executed at multiple prices with disclosed ranges from $807.85 up to $833.155, and the footnotes state each reported price is a weighted average for that lot. The filing includes an undertaking to provide per‑price quantities on request, which aids transparency about execution.

Because the filing reports sales only, there are no derivative positions or exercises disclosed in this Form 4.

Insider LILLY ENDOWMENT INC
Role 10% Owner
Sold 215,822 shs ($177.29M)
Type Security Shares Price Value
Sale Common Stock 5,388 $808.328 $4.36M
Sale Common Stock 3,233 $809.289 $2.62M
Sale Common Stock 2,263 $810.583 $1.83M
Sale Common Stock 7,226 $811.553 $5.86M
Sale Common Stock 18,465 $812.415 $15.00M
Sale Common Stock 13,770 $813.358 $11.20M
Sale Common Stock 14,307 $814.528 $11.65M
Sale Common Stock 10,847 $815.272 $8.84M
Sale Common Stock 4,784 $816.622 $3.91M
Sale Common Stock 4,137 $817.648 $3.38M
Sale Common Stock 2,750 $818.758 $2.25M
Sale Common Stock 4,315 $819.833 $3.54M
Sale Common Stock 3,800 $820.764 $3.12M
Sale Common Stock 2,400 $822.13 $1.97M
Sale Common Stock 6,609 $823.365 $5.44M
Sale Common Stock 8,090 $824.565 $6.67M
Sale Common Stock 18,710 $825.392 $15.44M
Sale Common Stock 18,986 $826.431 $15.69M
Sale Common Stock 14,549 $827.561 $12.04M
Sale Common Stock 23,151 $828.406 $19.18M
Sale Common Stock 14,341 $829.361 $11.89M
Sale Common Stock 4,868 $830.407 $4.04M
Sale Common Stock 2,365 $831.296 $1.97M
Sale Common Stock 5,668 $832.432 $4.72M
Sale Common Stock 800 $833.154 $667K
Holdings After Transaction: Common Stock — 95,352,412 shares (Direct)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $807.85 to $808.70, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), and (25) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $808.86 to $809.825, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $809.86 to $810.78, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.00 to $811.905, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.00 to $812.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $813.00 to $813.88, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.00 to $814.975, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $815.00 to $815.97, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $816.08 to $816.82, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $817.125 to $818.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $818.18 to $819.07, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $819.27 to $820.20, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $820.40 to $821.31, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.55 to $822.495, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.78 to $823.71, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.91 to $824.88, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.91 to $825.905, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.91 to $826.89, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.935 to $827.91, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.95 to $828.94, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.96 to $829.93, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.98 to $830.9675, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $831.00 to $831.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.00 to $832.98, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.11 to $833.155, inclusive.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LILLY ENDOWMENT INC
(Last) (First) (Middle)
2801 NORTH MERIDIAN STREET
(Street)
INDIANAPOLIS IN 46208-0068
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 S 5,388 D $808.328(1) 95,352,412 D
Common Stock 10/01/2025 S 3,233 D $809.289(2) 95,349,179 D
Common Stock 10/01/2025 S 2,263 D $810.583(3) 95,346,916 D
Common Stock 10/01/2025 S 7,226 D $811.553(4) 95,339,690 D
Common Stock 10/01/2025 S 18,465 D $812.415(5) 95,321,225 D
Common Stock 10/01/2025 S 13,770 D $813.358(6) 95,307,455 D
Common Stock 10/01/2025 S 14,307 D $814.528(7) 95,293,148 D
Common Stock 10/01/2025 S 10,847 D $815.272(8) 95,282,301 D
Common Stock 10/01/2025 S 4,784 D $816.622(9) 95,277,517 D
Common Stock 10/01/2025 S 4,137 D $817.648(10) 95,273,380 D
Common Stock 10/01/2025 S 2,750 D $818.758(11) 95,270,630 D
Common Stock 10/01/2025 S 4,315 D $819.833(12) 95,266,315 D
Common Stock 10/01/2025 S 3,800 D $820.764(13) 95,262,515 D
Common Stock 10/01/2025 S 2,400 D $822.13(14) 95,260,115 D
Common Stock 10/01/2025 S 6,609 D $823.365(15) 95,253,506 D
Common Stock 10/01/2025 S 8,090 D $824.565(16) 95,245,416 D
Common Stock 10/01/2025 S 18,710 D $825.392(17) 95,226,706 D
Common Stock 10/01/2025 S 18,986 D $826.431(18) 95,207,720 D
Common Stock 10/01/2025 S 14,549 D $827.561(19) 95,193,171 D
Common Stock 10/01/2025 S 23,151 D $828.406(20) 95,170,020 D
Common Stock 10/01/2025 S 14,341 D $829.361(21) 95,155,679 D
Common Stock 10/01/2025 S 4,868 D $830.407(22) 95,150,811 D
Common Stock 10/01/2025 S 2,365 D $831.296(23) 95,148,446 D
Common Stock 10/01/2025 S 5,668 D $832.432(24) 95,142,778 D
Common Stock 10/01/2025 S 800 D $833.154(25) 95,141,978 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $807.85 to $808.70, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), and (25) to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $808.86 to $809.825, inclusive.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $809.86 to $810.78, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.00 to $811.905, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.00 to $812.99, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $813.00 to $813.88, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.00 to $814.975, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $815.00 to $815.97, inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $816.08 to $816.82, inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $817.125 to $818.00, inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $818.18 to $819.07, inclusive.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $819.27 to $820.20, inclusive.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $820.40 to $821.31, inclusive.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.55 to $822.495, inclusive.
15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.78 to $823.71, inclusive.
16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.91 to $824.88, inclusive.
17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.91 to $825.905, inclusive.
18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.91 to $826.89, inclusive.
19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.935 to $827.91, inclusive.
20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.95 to $828.94, inclusive.
21. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.96 to $829.93, inclusive.
22. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.98 to $830.9675, inclusive.
23. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $831.00 to $831.84, inclusive.
24. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.00 to $832.98, inclusive.
25. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.11 to $833.155, inclusive.
Remarks:
This is the second of two Forms 4 filed by the Reporting Person on same date, October 2, 2025, representing transactions #31 through #55 of 55 total transactions.
/s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc. 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Lilly Endowment Inc. report for Eli Lilly (LLY) on this Form 4?

Lilly Endowment Inc. reported the sale of 215,822 shares of Eli Lilly common stock on 10/01/2025, with post‑transaction ownership of 95,141,978 shares.

At what prices were the Eli Lilly shares sold (LLY)?

The filing discloses weighted average prices per reported lot with ranges from $807.85 up to $833.155 across the transactions.

Who signed the Form 4 for these LLY transactions?

The Form 4 was signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc..

How many transactions does this Form 4 represent for LLY?

This filing represents transactions numbered 31–55 of 55 total transactions executed by the reporting person on the same date.

Does the Form 4 show any derivatives or option exercises for LLY?

No. Table II for derivative securities contains no reported transactions; only common stock dispositions are listed in this Form 4.